Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsDrreddyslaboratories

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Invest in Alembic Pharma, says Dipan Mehta

      Dipan Mehta, Member at BSE & NSE is of the view that one can invest in Alembic Pharma.

    • Prefer Glenmark Pharma, Syngene: Gaurang Shah

      According to Gaurang Shah of Geojit BNP Paribas Financial Services, one may prefer Glenmark Pharma and Syngene.

    • Top buzzing midcap stocks to trade on October 21

      Here are a few top buzzing midcap stocks picked by CNBC-TV18's analysts in trade today. We have Indiabulls Real Estate, Mphasis, Federal Bank, Torrent Pharma, Dr Reddys Laboratories & Aurobindo Pharma.

    • Buy Dr Reddy's Laboratories: Prakash Diwan

      Prakash Diwan of prakashdiwan.in is of the view that one can buy Dr Reddy's Laboratories.

    • Super Six stocks that can give handsome returns today

      Gaurav Ratnaparkhi of Sharekhan recommends buying Tata Comm with a target of Rs 452 and a stop loss at Rs 419 and Mahindra & Mahindra Financial Services with a target of Rs 249 and a stop loss at Rs 230.

    • Aurobindo Pharma, Sun Pharma preferred picks: Joshi

      Mayuresh Joshi of Angel Broking is of the view that Aurobindo Pharma and Sun Pharma are the preferred picks.

    • Dr Reddy's Labs top pick, says Mehraboon Irani

      Mehraboon Irani of Nirmal Bang Securities is of the view that Dr Reddy's Labs is the top pick.

    • Buy Dr Reddy's Laboratories, says Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Dr Reddy's Laboratories.

    • Buy pharma stocks on dips, says Rahul Shah

      Rahul Shah of Motilal Oswal is of the view that one can buy pharma stocks on decline.

    • Stick to frontline pharma, barring Sun Pharma: Jai Bala

      Jai Bala of 1857 Advisors recommends sticking to frontline pharma names barring Sun Pharmaceutical Industries.

    • Look at Dr Reddy's Labs, Aurobindo Pharma: Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can look at Dr Reddy's Laboratories, Aurobindo Pharma and Cadila Healthcare from the pharma space.

    • Hold Dr Reddy's Labs, says Mayuresh Joshi

      Mayuresh Joshi of Angel Broking recommends holding Dr Reddy's Labs.

    • Prefer Lupin, Dr Reddy's Labs for long term: Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one may prefer Lupin and Dr Reddy's Laboratories for long term.

    • Hold Ballarpur Industries, says Kunal Bothra

      According to Kunal Bothra of LKP Securities, one may hold Ballarpur Industries.

    • Buy pharma stocks: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying pharma stocks for investments including Sun Pharma.

    • Super Six stocks you can bet on September 28

      Hemen Kapadia of KRChoksey Securities is of the view that one may buy HDFC with a target of Rs 1194.

    • Buy Dr Reddy's Laboratories, says Sudarshan Sukhani

      According to Sudarshan Sukhani of s2analytics.com, one can buy Dr Reddy's Laboratories.

    • Strides Arcolab top pick, says Gautam Trivedi

      According to Gautam Trivedi, MD & CEO of Religare Capital Markets, Strides Arcolab is a top pick in the midcap pharma space.

    • Look at Dr Reddy's Lab, Sun Pharma: Prakash Diwan

      According to Prakash Diwan of prakashdiwan.in, one may look at Dr Reddy's Laboratories, Glenmark Pharma and Sun Pharma from the pharmaceutical space.

    • Buy pharma stocks, advises Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying phrama stocks including Cipla and Dr Reddy's Laboratories.

    • 6 stock ideas to liven up your trade

      Meghana V Malkan of malkansview.com is of the view that one may buy Ajanta Pharma with a target of Rs 1555.

    • Pick L&T, Dabur, Sun Pharma: Sharmila Joshi

      According to Sharmila Joshi of sharmilajoshi.com, one may prefer largecap stocks like Larsen and Toubro, Sun Pharma and Dabur India.

    • Buy pharma stocks, says Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that pharmaceutical is an opportunity.

    • Buy Dr Reddy's Laboratories, L&T: Manoj Murlidharan

      Manoj Murlidharan of Religare Securities recommends buying Dr Reddy's Laboratories current month futures with a target of Rs 4102 and Larsen & Toubro with a target of Rs 1608-1610.

    • Is it the right time to enter pharma stocks?

      The pharma sector has seen the biggest correction over the past one month. The index itself has seen a 5 percent fall from the top. Abhishek Sharma, a pharma analyst at IIFL, gave his views on Dr Reddy's, Glenmark, Cipla and Sun Pharma.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347